Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on Transdigm Group (TDG – Research ...

Full Year 2024 Results Key Financial Results Revenue: US$7.94b (up 21% from FY 2023).

TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...

TransDigm Group Inc ( NYSE:TDG) showcases robust revenue growth and profitability in its latest 10-K filing. With a strong aftermarket presence, TDG capitalizes on long-term revenue streams. Strategic ...

Good day, and thank you for standing by. Welcome to the fourth quarter 2024 TransDigm Group earnings conference call. (Operator Instructions) Please be advised that today's conference is being ...

TransDigm operates as a private-equity-like public company, so its capital allocation is meaningfully different than most aerospace and defense companies we cover. TransDigm maintains a significant ...

TransDigm Group Inc (TDG) surpasses fiscal 2024 guidance with strong revenue growth, a substantial special dividend, and strategic capital allocation.

Currently trading with a volume of 289,108, the TDG's price is down by -3.9%, now at $1328.7. RSI readings suggest the stock ...

Aerospace supplier TransDigm Group on Thursday forecast its annual profit and revenue below analysts' expectations and highlighted risks around the pace of commercial jetliner production as the ...